Bringing a medical device to the United States market involves more than achieving regulatory clearance or approval. While FDA approval is often seen as the primary milestone, it does not guarantee commercial success. In practice, reimbursement determines whether a device will be adopted, used and financially viable. Without appropriate coverage, coding and payment, hospitals and clinicians are unlikely to use a new technology regardless of its clinical benefit. Understanding the US medical device reimbursement landscape is therefore essential for manufacturers, particularly those entering the market for the first time.
The Structure of the US Healthcare System
The US healthcare system is complex and fragmented, with multiple payers operating under different rules and frameworks. Healthcare is funded primarily through two channels, commercial insurance and federal healthcare programmes.
Commercial insurance includes employer sponsored plans and individual policies. These private payers make independent coverage and payment decisions, although they often consider Medicare policies as a reference point.
Federal healthcare programmes include Medicare, Medicaid and the Children’s Health Insurance Program. These programmes are administered by the Centers for Medicare and Medicaid Services, which plays a central role in defining reimbursement structures, policies and coding systems. Eligibility and benefits vary across programmes, with Medicaid and CHIP allowing individual states to determine certain optional benefits within federal guidelines.
Understanding Coverage, Coding and Payment
Reimbursement is built on three interconnected components, coverage, coding and payment. Before exploring each element in detail, it is important to recognise that success requires alignment across all three.
Coverage determines whether a device or service is eligible for reimbursement. Coding provides the mechanism for identifying the device or procedure within billing systems. Payment defines how much providers are reimbursed for using the device.
If any one of these components is missing or misaligned, reimbursement may fail even if the device has regulatory approval.
What Coverage Means in Practice
Coverage refers to whether a payer will reimburse a device or service. Medicare coverage is defined by law, specifically within the Social Security Act, while Medicaid and CHIP operate within a framework of mandatory and optional benefits.
Coverage decisions are made through National Coverage Determinations and Local Coverage Determinations. National Coverage Determinations apply across the entire Medicare system, while Local Coverage Determinations are issued by Medicare Administrative Contractors and apply regionally where no national policy exists.
Commercial payers historically follow Medicare decisions but are increasingly making independent coverage determinations based on clinical evidence. In some cases, private insurers may cover new technologies before Medicare has issued a formal decision.
Coverage decisions are influenced by evidence demonstrating clinical effectiveness, improvement in patient outcomes and potential to reduce downstream healthcare costs.
Which Devices Are Covered
Devices that have received FDA clearance or approval through 510(k), De Novo or PMA pathways are generally eligible for coverage consideration. In addition, certain investigational devices may be covered under specific conditions, such as Category B Investigational Device Exemptions or non significant risk studies approved by institutional review boards.
However, eligibility for coverage does not guarantee that reimbursement will be granted. Evidence requirements, payer policies and clinical adoption all influence final decisions.
The Role of Coding in Reimbursement
Coding is a critical but often misunderstood component of reimbursement. It provides the standardised language used to describe medical procedures, services and products for billing and claims processing.
Several coding systems are used within the US healthcare system. Current Procedural Terminology codes are maintained by the American Medical Association and describe medical procedures and services. These codes are divided into categories, including permanent codes for established procedures and temporary codes for emerging technologies.
Healthcare Common Procedure Coding System codes are maintained by the Department of Health and Human Services and cover products, supplies and services not included in CPT codes, such as durable medical equipment and prosthetics.
International Classification of Diseases codes are used to describe diagnoses and inpatient procedures. These codes support clinical documentation and reimbursement decisions by linking medical necessity to billed services.
Without appropriate coding, providers cannot submit claims, which effectively prevents reimbursement.
Understanding Payment Systems
Payment refers to the reimbursement received by providers for delivering healthcare services or using medical devices. Unlike some healthcare systems, there is no single payment method or amount in the United States.
Payment varies depending on the payer, the provider, the patient’s condition and the site of care. For example, payment rates may differ between inpatient and outpatient settings or between hospitals and physician offices.
Fee for Service remains one of the most common reimbursement models. Under this approach, providers are reimbursed based on the services delivered. Other models may include bundled payments or value based reimbursement, depending on the payer and clinical context.
Importantly, payers typically reimburse providers rather than paying manufacturers directly. This means that manufacturers must ensure that reimbursement supports provider adoption.
Why Reimbursement Strategy Is Critical
A reimbursement strategy should be developed early in the product lifecycle. Waiting until after regulatory approval can lead to delays in market adoption and reduced commercial success.
Without a clear reimbursement pathway, manufacturers may face challenges in achieving profitability, as providers may not be willing to use a device that is not reimbursed. Payers may also be reluctant to cover new technologies without sufficient evidence of value. Patients may face higher out of pocket costs or limited access to innovative treatments.
A structured reimbursement strategy aligns clinical evidence generation, regulatory planning and market access activities. It ensures that devices are not only approved but also accessible and financially viable within the healthcare system.
Steps in Building a Reimbursement Strategy
Developing a reimbursement strategy involves several key steps. Before listing these steps, it is important to recognise that reimbursement planning should be integrated with overall product development and regulatory strategy.
Manufacturers should begin by analysing the clinical and economic value of the device, including its impact on patient outcomes and healthcare costs. Evidence generation plans should be designed to support both regulatory approval and reimbursement requirements.
Coding pathways must be identified early, including whether existing codes can be used or whether new codes must be obtained. Engagement with payers, clinicians and other stakeholders helps to understand coverage expectations and adoption barriers.
Manufacturers should also evaluate payment pathways, including potential eligibility for additional payments such as new technology add on payments. These mechanisms can support early adoption while longer term reimbursement structures are established.
Key Challenges in the US Reimbursement Landscape
The US reimbursement system presents several challenges. Its complexity requires manufacturers to navigate multiple payers, policies and coding systems. Variability in coverage and payment creates uncertainty and requires tailored strategies for different markets.
Regulatory approval and reimbursement are separate processes, each with its own evidence requirements. Manufacturers must therefore plan for both simultaneously.
Delays in coding or coverage decisions can slow market adoption, even when clinical evidence is strong. Understanding these challenges and addressing them proactively is essential for successful market entry.
Strategic Implications for Manufacturers
Reimbursement is not a secondary consideration. It is a core component of market access. Manufacturers that integrate reimbursement strategy into early development are more likely to achieve successful adoption and sustained commercial performance.
This requires cross functional collaboration between regulatory, clinical, health economics and commercial teams. It also requires ongoing engagement with stakeholders across the healthcare system.
LFH supports medical device companies in developing and executing effective US reimbursement strategies, aligning regulatory approval with coverage, coding and payment pathways. Our team helps manufacturers navigate complexity, generate the right evidence and position their technologies for successful adoption in the US healthcare system.
FAQs – US Medical Device Reimbursement
Is FDA approval enough to ensure reimbursement in the US?
No, reimbursement requires separate coverage, coding and payment alignment.
What are the three components of reimbursement?
Coverage, coding and payment.
Who makes coverage decisions in the US?
Medicare, Medicaid, commercial payers and regional contractors all play a role.
Do payers reimburse manufacturers directly?
No, reimbursement is typically paid to healthcare providers.
Can new devices be covered before Medicare makes a decision?
Yes, some commercial payers may provide coverage based on their own evidence review.
Why is coding important for reimbursement?
Without appropriate codes, providers cannot submit claims for reimbursement.
